


La molécule du mois - What molecule am I ?



Valbenazine

Valbenazine is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor that modulates dopamine release during nerve communication. The pharmacological target VMAT2 may play an important role in the treatment of tardive dyskinesia (TD) used to describe an involuntary movement disorder caused by cumulative exposure to antipsychotic medications and other related drugs. Valbenazine significantly improved tardive dyskinesia in individuals with psychotic disorders.

Valbenazine was approved by FDA in April 2017 (Ingrezza®) as the first medication for the treatment of tardive dyskinesia (TD) .

Contribution : David MONTOIR & Abdallah HAMZE May 2017